Agios (AGIO) furnishes press release for quarter ended Sep 30, 2025

Agios Pharmaceuticals (AGIO) furnished an 8-K announcing it issued a press release with results for the quarter ended September 30, 2025 and other business highlights.

Accepted by SEC EDGAR 10/30/2025 - 06:32 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Agios Pharmaceuticals (AGIO) furnished an 8-K announcing it issued a press release with results for the quarter ended September 30, 2025 and other business highlights. The press release is provided as Exhibit 99.1. The company states this information, including Exhibit 99.1, is furnished and not deemed “filed” for purposes of Section 18 of the Exchange Act, and is not incorporated by reference into other filings except as specifically referenced.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Agios (AGIO) announce in this 8-K?

Agios furnished a press release with results for the quarter ended September 30, 2025 and other business highlights as Exhibit 99.1.

Where can I find the detailed results referenced by Agios (AGIO)?

The detailed information is in Exhibit 99.1, the press release furnished with the 8-K.

Is the Agios (AGIO) press release considered 'filed' with the SEC?

No. The information, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act.

What period does the Agios (AGIO) press release cover?

It covers the company’s results for the quarter ended September 30, 2025.

What is Agios (AGIO)’s trading venue and ticker?

Agios common stock trades on the Nasdaq Global Select Market under the ticker AGIO.

What exhibits are included with this Agios (AGIO) 8-K?

Exhibit 99.1 (press release issued October 30, 2025) and Exhibit 104 (Cover Page Inline XBRL data).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001439222FALSE00014392222025-10-302025-10-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 30, 2025

Agios Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-36014

26-0662915

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

88 Sidney Street,

Cambridge,

MA

02139

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (617) 649-8600

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

			☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
			☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
			☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
			☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common Stock, Par Value $0.001 per share

AGIO

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company			☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On October 30, 2025, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter ended September 30, 2025 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.			Description
99.1			Press release issued October 30, 2025
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			AGIOS PHARMACEUTICALS, INC.
Date: October 30, 2025			By:			/s/ Brian Goff
						Brian Goff Chief Executive Officer